J&J pays $3.4 billion for robotics firm AurisJohnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that Share XJ&J pays $3.4 billion for robotics firm Aurishttps://pharmaphorum.com/news/jj-pays-robotics-firm-auris/
BMS pulls Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line Share XBMS pulls Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/
FDA extends review of Merck & Co’s Keytruda in lung cancer useUS regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain Share XFDA extends review of Merck & Co’s Keytruda in lung cancer usehttps://pharmaphorum.com/news/fda-review-merck-keytruda-lung-cancer/
AZ’s cancer drug fails again, Roche’s rival gets new useAstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved Share XAZ’s cancer drug fails again, Roche’s rival gets new usehttps://pharmaphorum.com/news/azs-cancer-imfinzi-fail/
AbbVie suffers fresh setback with lung cancer drug Rova-TAbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer Share XAbbVie suffers fresh setback with lung cancer drug Rova-Thttps://pharmaphorum.com/news/abbvie-suffers-fresh-setback-with-lung-cancer-drug-rova-t/
Thousands to benefit as NHS funds Keytruda lung cancer comboNICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with Share XThousands to benefit as NHS funds Keytruda lung cancer combohttps://pharmaphorum.com/news/thousands-to-benefit-as-nhs-funds-keytruda-lung-cancer-combo/
AstraZeneca’s immunotherapy fails in key lung cancer trialAstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line Share XAstraZeneca’s immunotherapy fails in key lung cancer trialhttps://pharmaphorum.com/news/astrazenecas-imfinzi-fails-in-key-lung-cancer-trial/
J&J buys novel lung cancer drug from South Korea’s YuhanJanssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small Share XJ&J buys novel lung cancer drug from South Korea’s Yuhanhttps://pharmaphorum.com/news/jj-buys-novel-lung-cancer-drug-from-south-koreas-yuhan/
FDA green lights Pfizer’s Lorbrena for aggressive lung cancerPfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer. The US Food Share XFDA green lights Pfizer’s Lorbrena for aggressive lung cancerhttps://pharmaphorum.com/news/fda-green-lights-pfizers-lorbrena-for-aggressive-lung-cancer/
